Company profile
Incyte Corporation
NASDAQ: INCY · Healthcare · Biotechnology
#61 of 1,418 Healthcare companies by revenue67th-percentile growth
EA Score
90AFH 90DQ 95GM 75SS 94
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$5.4B
Rev growth YoY (TTM)
+21.5%
Net income (FY)
$1.3B
Employees
2,844
as of 2026-08-05
Market cap
$24.4B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$5.1B$5.1B2025
Net income$1.3B$1.3B2025
Operating income$1.5B$1.5B2025
Total assets$7.0B$7.0B2025
Liabilities$1.8B$1.8B2025
Equity$5.2B$5.2B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
J A K A F I71%
OPZELURA14%
Milestone And Contract Revenue3%
Olumiant Royalty3%
M I N J U V I3%
I C L U S I G3%
By geography
U [S]94%
Europe6%
The read
What is Incyte Corporation’s revenue?
Incyte Corporation booked $5.1B in FY2025 revenue, growing 21% year over year — faster than most Healthcare companies we track, at a 25.0% net margin.
Peers · Healthcare
BeOne Medicines AG75B+PACS Group, Inc.53DResMed Inc.88ABausch + Lomb Corporation67BThe Ensign Group, Inc.80B+Elanco Animal Health Incorporated66BNeighbors
New Castle →Key facts
CEOWilliam J. Meury
SectorHealthcare
IndustryBiotechnology
HeadquartersWilmington, DE
ExchangeNASDAQ: INCY
Employees2,844
IPO date1993-11-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.